查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1990301

鴉片類藥物市場：2026-2032年全球市場預測（按鴉片類藥物類型、給藥途徑、應用和最終用戶分類）

Opioids Market by Opioid Types, Mode of Administration, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，鴉片類藥物市場價值將達到 224.4 億美元，到 2026 年將成長至 233.7 億美元，到 2032 年將達到 299.6 億美元，複合年成長率為 4.21%。

主要市場統計數據
基準年 2025 224.4億美元
預計年份：2026年 233.7億美元
預測年份 2032 299.6億美元
複合年成長率 (%) 4.21%

為決策者提供鴉片類藥物療法現狀的簡要概述：概述臨床需求、監管壓力和策略重點。

在治療需求、安全問題和不斷變化的法規結構等複雜因素交織的背景下，鴉片類藥物治療的現狀仍然受到臨床、監管和政策相關人員的密切關注。本報告的引言概述了所使用的分析觀點，將鴉片類藥物置於現代醫療路徑中，並強調需要在有效鎮痛和麻醉的同時，加強對濫用和不利事件的防範。透過整合臨床實踐趨勢、監管訊號和供應鏈現狀，本報告指出了藥物研發人員、醫療服務提供者和公共衛生機構面臨的關鍵挑戰和機會。

臨床實踐、法律規範和給藥方式的演變正在重塑所有醫療保健機構中鴉片類藥物療法的開發和合理使用。

鴉片類藥物治療領域正經歷變革性的轉變，重塑臨床實務、產品研發和法律規範。合成鴉片類藥物化學的進步，加上監測和處方管控的加強，正在加速受監管製劑的重新設計以及濫用預防技術的探索。同時，給藥系統的創新，例如改良的經皮基質和標靶注射製劑，正在重新定義所有醫療機構中鎮痛和麻醉藥物的給藥方式。

評估 2025 年貿易關稅調整對鴉片類藥物供應鏈、採購經濟和臨床取得策略的累積影響。

美國於2025年實施的關稅措施對整個鴉片類藥物供應鏈產生了累積影響，其連鎖反應波及原料採購、生產物流和臨床採購等各個環節。某些前驅物和成品進口關稅的提高加劇了製造商對投入成本的擔憂，促使他們重新評估供應商組合和合約條款。為此，許多相關人員加快了多元化策略的實施，優先考慮本地採購並選擇替代供應商，以減輕關稅帶來的成本負擔。

多維分割分析揭示治療領域、給藥途徑、臨床應用和最終用戶部署對策略的影響。

一套精細的細分框架揭示了治療藥物研發和臨床應用的分歧點和交匯點，為策略優先排序提供了切實可行的觀點。以鴉片類藥物類型進行分析，突顯了天然鴉片類藥物（如可待因和氫可酮）、半合成鴉片類藥物（如氫可酮和羥考酮）以及全合成鴉片類藥物（如Fentanyl和美沙酮）之間的差異。每類藥物都有其獨特的藥理學特性、監管控制和臨床應用案例，這些都會影響製劑和監測要求。

世界各地管理體制、醫療保健基礎設施和支付方優先事項的差異如何影響鴉片類藥物產品開發和取得的個人化策略。

區域趨勢對臨床實務和商業性管道均有影響，導致優先事項和實施方案有顯著差異。在美洲，臨床指引和支付方框架強調合理用藥，同時確保在急性照護的各個階段都能持續獲得必要的止痛藥。這使得風險緩解策略和真實世界數據（REW）的收集尤其重要。同時，在歐洲、中東和非洲，監管差異和不同的報銷模式導致新製劑和濫用預防技術的引入曲線存在差異，因此需要製定針對特定區域的市場准入和監管合規策略。

從公司層面的策略應對措施來看，我們可以看到通用關注安全創新、一體化製造和證據生成等優先事項，以維持臨床實踐的可及性。

鴉片類藥物治療生態系統中的主要企業正在展現出多樣化的策略性應對措施，這些措施為競爭對手和合作夥伴都提供了寶貴的經驗。產業領導企業正在投資於能夠降低濫用風險和改善安全監測的製劑技術，同時也不斷提升其無菌生產和受控藥品物流能力。一些企業正在尋求與醫療設備製造商建立合作關係，將給藥方案與藥理學結合，以提高給藥的準確性和患者的依從性。

為領導者制定可操作的策略重點，重點在於安全至上的創新、價值鏈韌性和協作管理，以保護獲取和價值。

產業領導者必須採取一系列切實可行的措施，將洞察轉化為強大的競爭優勢，同時確保病患安全和合規性。首先，他們應優先開發和推出用於預防濫用和提高安全性的製劑，並建立健全的藥物安全檢測系統，及時產生真實世界數據，以支持與臨床醫生和保險公司的溝通。其次，他們必須透過供應商多元化、策略性庫存緩衝以及對區域生產合作夥伴進行認證等方式，投資於供應鏈韌性，以降低貿易和關稅波動帶來的風險。

採用嚴謹的混合方法，結合證據整合、相關人員訪談和情境分析，可以得出合理的策略結論和建議。

本分析的調查方法整合了對同儕審查的臨床文獻、監管申報文件和公共文件的系統性回顧，以及對臨床、生產和監管相關人員的結構化訪談。資料收集優先考慮記錄療效、安全性概況和政策變化的資訊來源，而綜合分析則強調對不同證據流進行檢驗，以提高推論的有效性。定性訪談旨在收集有關供應鏈、製劑挑戰和推廣障礙的實際觀點，使本報告能夠將策略主題與現實世界聯繫起來。

維持鴉片類藥物治療的可近性和創新性面臨著相互補充的挑戰：臨床安全、商業性韌性和協作管理。

總之，鴉片類藥物治療領域正處於轉捩點，需要各方攜手合作，推進安全創新、增強供應鏈穩健性並加強跨部門協作。製劑科學和給藥技術的革新為改善治療效果提供了契機，而不斷變化的監管和貿易環境也帶來了新的限制因素，因此需要製定靈活的商業性和營運策略。將實證實務與藥物管理計畫和穩健的採購慣例結合，能夠幫助相關人員在推進公共衛生目標的同時，並保障臨床實務的可近性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：鴉片類藥物市場（依鴉片類藥物類型分類）

  • 天然鴉片類藥物
    • 可待因
    • 氫可酮
  • 半合成鴉片類藥物
    • 氫可酮
    • 羥考酮
  • 合成鴉片類藥物
    • Fentanyl
    • 梅塔頓

第9章：依給藥途徑分類的鴉片類藥物市場

  • 口服
    • 膠囊
    • 藥片
  • 腸外給藥
    • 肌肉內部
    • 靜脈
  • 經皮給藥

第10章：鴉片類藥物市場：依應用領域分類

  • 麻醉
    • 全身麻醉
    • 局部麻醉
  • 止咳藥
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛

第11章：鴉片類藥物市場：依最終用戶分類

  • 醫療機構
    • 診所
    • 醫院
  • 家庭醫療保健
  • 研究機構

第12章：鴉片類藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：鴉片類藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：鴉片類藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國鴉片類藥物市場

第16章：中國鴉片類藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alvogen
  • Apotex Inc.
  • Biesterfeld SE
  • Daiichi Sankyo Company, Limited
  • Elite Pharmaceuticals, Inc.
  • Endo International plc
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Humanwell Healthcare（Group）Co., Ltd.
  • Indivior PLC
  • Johnson & Johnson Services, Inc.
  • Johnson Matthey Group
  • Kyowa Hakko Kirin Co. Ltd.
  • Mallinckrodt plc
  • Nutriband Inc.
  • Pfizer Inc.
  • Piramal Pharma Limited
  • Purdue Pharma LP
  • QuVa Pharma, Inc
  • SCA Pharma
  • Spectrum Chemical Mfg. Corp.
  • Teva Pharmaceutical Industries Ltd.
  • Tofigh Daru Research & Engineering Company
  • Verve HumanCare Laboratories
  • Viatris Inc.
Product Code: MRR-CB04E05659AC

The Opioids Market was valued at USD 22.44 billion in 2025 and is projected to grow to USD 23.37 billion in 2026, with a CAGR of 4.21%, reaching USD 29.96 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 22.44 billion
Estimated Year [2026] USD 23.37 billion
Forecast Year [2032] USD 29.96 billion
CAGR (%) 4.21%

A concise orientation to the opioid therapeutics landscape framing clinical imperatives, regulatory pressure, and strategic priorities for decision-makers

The opioid therapeutics landscape continues to prompt intense scrutiny from clinical, regulatory, and policy stakeholders, driven by complex intersections of therapeutic necessity, safety concerns, and evolving regulatory frameworks. This introduction sets out the analytical lens used in the report, situating opioids within contemporary care pathways while recognizing the imperative to balance effective analgesia and anesthesia against heightened vigilance for misuse and adverse outcomes. By synthesizing clinical practice trends, regulatory signals, and supply chain realities, the report frames the primary challenges and opportunities facing pharmaceutical developers, healthcare providers, and public health agencies.

Throughout this analysis, emphasis is placed on evidence-based evaluation of therapeutic classes, routes of administration, clinical applications, and end-user dynamics. The intent is to provide decision-makers with a clear, structured understanding of where clinical demand intersects with regulatory pressures and innovation trajectories. With that orientation established, subsequent sections explore transformative shifts, policy impacts, segmentation insights, and regional dynamics, all designed to inform strategic planning, clinical protocol development, and investment prioritization.

How evolving clinical practice, regulatory oversight, and delivery innovation are reshaping opioid therapy development and stewardship across care settings

The landscape of opioid therapeutics is in the midst of transformative shifts that recalibrate clinical practice, product development, and regulatory oversight. Advances in synthetic opioid chemistry, coupled with intensified monitoring and prescription controls, have encouraged the redevelopment of controlled formulations and the exploration of abuse-deterrent technologies. At the same time, innovation in delivery systems, such as refined transdermal matrices and targeted parenteral formulations, is redefining how analgesia and anesthesia are administered across care settings.

Concurrently, payer and provider policies are shifting toward evidence-based protocols that emphasize multimodal pain management and stewardship programs designed to minimize long-term opioid exposure. These trends are accelerating the adoption of alternative pain pathways and driving more rigorous post-marketing surveillance, thereby increasing the bar for new product entry and lifecycle management. As a result, developers and clinical leaders must adapt to an environment that rewards demonstrable safety improvements, real-world outcomes data, and collaborative approaches that integrate pharmacy, surgery, and primary care perspectives.

Assessing the cumulative ramifications of 2025 trade tariff adjustments on opioid supply chains, procurement economics, and clinical access strategies

The United States tariff measures implemented in 2025 exerted a cumulative influence across the opioid supply chain, reverberating through raw material sourcing, manufacturing logistics, and clinical procurement. Increased import levies on certain precursors and finished formulations elevated input cost considerations for manufacturers, prompting reassessments of supplier portfolios and contractual terms. In response, many stakeholders accelerated diversification strategies that prioritized regional sourcing and qualified alternate suppliers to mitigate exposure to tariff-driven costs.

These trade policy shifts also affected distribution economics and inventory strategies for hospitals, clinics, and home healthcare providers, who faced amplified scrutiny of procurement spend and inventory turn. In turn, manufacturers and distributors revisited pricing, contractual rebates, and rebate timing to preserve access while managing margin pressure. Importantly, regulatory authorities and industry associations emphasized compliance and transparency around cost pass-through to ensure continued patient access to critical therapies. The net effect underscores a heightened need for resilient supply chain design, proactive regulatory engagement, and commercial agility to navigate evolving trade and tariff environments without compromising clinical continuity.

A multi-dimensional segmentation analysis clarifying therapeutic categories, delivery pathways, clinical applications, and end-user deployment implications for strategy

A nuanced segmentation framework reveals where therapeutic development and clinical deployment diverge and converge, providing practical lenses for strategic prioritization. When parsed by opioid types, distinctions emerge between natural opiates such as codeine and morphine, semi-synthetic agents exemplified by hydrocodone and oxycodone, and fully synthetic compounds including fentanyl and methadone, each category carrying distinct pharmacology, regulatory controls, and clinical use cases that influence formulation and monitoring requirements.

Equally informative is segmentation by mode of administration, which contrasts oral routes-implemented in capsules and tablets-with parenteral options that require intramuscular or intravenous delivery, and with transdermal systems designed for sustained release. These administration pathways create divergent requirements for dosing accuracy, abuse deterrence, and device compatibility. Application-focused segmentation differentiates anesthesia applications, both general and regional, from indications like cough suppression and pain management, where acute and chronic pain profiles demand tailored therapeutic strategies and monitoring. Finally, end-user segmentation highlights deployment environments spanning healthcare facilities, where clinics and hospitals each present different formularies and utilization patterns, home healthcare settings that prioritize portability and safety, and research institutes that drive clinical innovation and early-stage evaluation. Together, these segmentation lenses support targeted product development, differentiated commercial strategies, and informed clinical policy design.

How divergent regulatory regimes, healthcare infrastructures, and payer priorities across global regions shape tailored strategies for opioid product development and access

Regional dynamics shape both clinical practice and commercial pathways, with discernible differences that affect prioritization and execution. In the Americas, clinical guidelines and payer frameworks emphasize stewardship while enabling continued access to essential analgesics across acute care settings; this creates a climate where risk mitigation strategies and real-world evidence collection are particularly salient. Meanwhile, in Europe, Middle East & Africa, regulatory heterogeneity and diverse reimbursement models create differentiated adoption curves for new formulations and abuse-deterrent technologies, necessitating tailored market-entry and regulatory strategies.

Across Asia-Pacific, rapid modernization of healthcare infrastructure and expanding clinical research capacity have catalyzed interest in novel delivery systems and localized manufacturing partnerships. The synthesis of these regional patterns suggests that successful strategies will blend global evidence generation with region-specific regulatory engagement and supply chain redundancy. Moreover, cross-regional learning, where best practices in stewardship and device integration migrate between geographies, will further influence how therapies are adopted and optimized at the point of care.

Company-level strategic responses reveal converging priorities on safety innovation, integrated manufacturing, and evidence generation to sustain clinical access

Key companies within the opioid therapeutics ecosystem demonstrate varied strategic responses that offer instructive lessons for competitors and collaborators. Industry leaders are investing in formulation technologies that reduce abuse potential and improve safety monitoring while simultaneously expanding capabilities in sterile manufacturing and controlled-substance logistics. A subset of organizations is pursuing partnerships with device manufacturers to couple pharmacology with delivery solutions that enhance dosing precision and patient adherence.

In parallel, several established firms are reallocating resources toward post-market evidence generation and pharmacovigilance systems to support regulatory filings and payer negotiations. Smaller, innovation-focused companies commonly concentrate on niche clinical applications or novel chemical entities that address unmet needs in anesthesia or chronic pain, while contract development and manufacturing organizations serve as critical enablers by providing specialized capabilities for controlled-substance production. Collectively, these company-level strategies underscore the primacy of safety innovation, regulatory collaboration, and integrated supply chain competencies.

Practical strategic priorities for leaders focused on safety-driven innovation, supply chain resilience, and collaborative stewardship to protect access and value

Industry leaders must adopt a set of actionable steps that translate insights into defensible advantage while maintaining patient safety and regulatory compliance. First, prioritize development and deployment of abuse-deterrent and safety-enhanced formulations alongside robust pharmacovigilance frameworks that generate timely real-world evidence to support clinical and payer dialogues. Second, invest in supply chain resilience through supplier diversification, strategic stock buffering, and qualification of regional manufacturing partners to reduce exposure to trade and tariff volatility.

Third, coordinate cross-functional engagement among clinical leaders, formulary committees, and payer representatives to design stewardship programs that align clinical outcomes with responsible prescribing. Fourth, pursue technology partnerships that integrate drug-device combinations and digital adherence tools to differentiate therapeutic offerings and improve patient monitoring. Finally, maintain proactive regulatory engagement and transparent communication with public health stakeholders to accelerate approvals and sustain access while demonstrating commitment to mitigating misuse and adverse outcomes. These combined actions will strengthen competitive positioning and uphold clinical responsibility.

A rigorous mixed-methods approach combining evidence synthesis, stakeholder interviews, and scenario analysis to produce defensible strategic conclusions and recommendations

The research methodology underpinning this analysis integrates systematic review of peer-reviewed clinical literature, regulatory filings, and public policy documents with structured interviews conducted across clinical, manufacturing, and regulatory stakeholders. Data collection prioritized sources that document therapeutic performance, safety profiles, and policy shifts, and synthesis emphasized triangulation among diverse evidence streams to strengthen inference validity. Qualitative interviews were designed to capture operational perspectives on supply chains, formulation challenges, and adoption barriers, enabling the report to connect strategic themes with on-the-ground realities.

Analytical approaches included thematic coding of stakeholder interviews, comparative assessment of regulatory frameworks, and scenario-based evaluation of trade and procurement impacts. Throughout, the methodology emphasized transparency in source attribution and reproducibility in analytic steps, allowing practitioners to trace conclusions back to primary evidence. Where appropriate, sensitivity analyses were conducted to test robustness of narrative conclusions against alternative policy or supply chain scenarios, ensuring that recommendations remain actionable across plausible futures.

Converging imperatives for clinical safety, commercial resilience, and collaborative stewardship to sustain access and innovation in opioid therapeutics

In conclusion, the opioid therapeutics sector is at an inflection point that demands concerted attention to safety innovation, supply chain robustness, and cross-sector collaboration. Transformations in formulation science and delivery technologies present opportunities to improve therapeutic outcomes while regulatory and trade developments impose new constraints that require adaptive commercial and operational strategies. By integrating evidence generation with stewardship programs and resilient sourcing practices, stakeholders can preserve clinical access while advancing public health objectives.

Moving forward, success will depend on organizations that align product development with demonstrable safety advantages, cultivate regional manufacturing and distribution flexibility, and invest in partnerships that enhance monitoring and adherence. The recommendations presented herein offer a pathway to reconcile clinical necessity with societal expectations, enabling responsible stewardship and sustained access to essential therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Opioids Market, by Opioid Types

  • 8.1. Natural Opiates
    • 8.1.1. Codeine
    • 8.1.2. Morphine
  • 8.2. Semi-Synthetic Opioids
    • 8.2.1. Hydrocodone
    • 8.2.2. Oxycodone
  • 8.3. Synthetic Opioids
    • 8.3.1. Fentanyl
    • 8.3.2. Methadone

9. Opioids Market, by Mode of Administration

  • 9.1. Oral Administration
    • 9.1.1. Capsules
    • 9.1.2. Tablets
  • 9.2. Parenteral Administration
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
  • 9.3. Transdermal Administration

10. Opioids Market, by Application

  • 10.1. Anesthesia
    • 10.1.1. General Anesthesia
    • 10.1.2. Regional Anesthesia
  • 10.2. Cough Suppression
  • 10.3. Pain Management
    • 10.3.1. Acute Pain
    • 10.3.2. Chronic Pain

11. Opioids Market, by End-User

  • 11.1. Healthcare Facilities
    • 11.1.1. Clinics
    • 11.1.2. Hospitals
  • 11.2. Home Healthcare
  • 11.3. Research Institutes

12. Opioids Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Opioids Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Opioids Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Opioids Market

16. China Opioids Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Alvogen
  • 17.7. Apotex Inc.
  • 17.8. Biesterfeld SE
  • 17.9. Daiichi Sankyo Company, Limited
  • 17.10. Elite Pharmaceuticals, Inc.
  • 17.11. Endo International plc
  • 17.12. Fresenius SE & Co. KGaA
  • 17.13. Hikma Pharmaceuticals PLC
  • 17.14. Humanwell Healthcare (Group) Co., Ltd.
  • 17.15. Indivior PLC
  • 17.16. Johnson & Johnson Services, Inc.
  • 17.17. Johnson Matthey Group
  • 17.18. Kyowa Hakko Kirin Co. Ltd.
  • 17.19. Mallinckrodt plc
  • 17.20. Nutriband Inc.
  • 17.21. Pfizer Inc.
  • 17.22. Piramal Pharma Limited
  • 17.23. Purdue Pharma L.P.
  • 17.24. QuVa Pharma, Inc
  • 17.25. SCA Pharma
  • 17.26. Spectrum Chemical Mfg. Corp.
  • 17.27. Teva Pharmaceutical Industries Ltd.
  • 17.28. Tofigh Daru Research & Engineering Company
  • 17.29. Verve HumanCare Laboratories
  • 17.30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPIOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPIOIDS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OPIOIDS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPIOIDS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OPIOIDS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES OPIOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA OPIOIDS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OPIOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS OPIOIDS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 217. GCC OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 219. GCC OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 220. GCC OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. GCC OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. GCC OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. GCC OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 227. GCC OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 228. GCC OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 256. G7 OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. G7 OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 258. G7 OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 259. G7 OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 260. G7 OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. G7 OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. G7 OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. G7 OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. G7 OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 266. G7 OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 267. G7 OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 268. G7 OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 269. NATO OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. NATO OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 271. NATO OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 272. NATO OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 273. NATO OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. NATO OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. NATO OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. NATO OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. NATO OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 279. NATO OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 280. NATO OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 281. NATO OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES OPIOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA OPIOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA OPIOIDS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2032 (USD MILLION)